264 reports of this reaction
2.3% of all CABOTEGRAVIR reports
#6 most reported adverse reaction
VIROLOGIC FAILURE is the #6 most commonly reported adverse reaction for CABOTEGRAVIR, manufactured by ViiV Healthcare Company. There are 264 FDA adverse event reports linking CABOTEGRAVIR to VIROLOGIC FAILURE. This represents approximately 2.3% of all 11,616 adverse event reports for this drug.
Patients taking CABOTEGRAVIR who experience virologic failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIROLOGIC FAILURE is a less commonly reported adverse event for CABOTEGRAVIR, but still significant enough to appear in the safety profile.
In addition to virologic failure, the following adverse reactions have been reported for CABOTEGRAVIR:
The following drugs have also been linked to virologic failure in FDA adverse event reports:
VIROLOGIC FAILURE has been reported as an adverse event in 264 FDA reports for CABOTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIROLOGIC FAILURE accounts for approximately 2.3% of all adverse event reports for CABOTEGRAVIR, making it a notable side effect.
If you experience virologic failure while taking CABOTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.